PDCD1 and squamous cell carcinoma: Furthermore, in-depth profiling of T cell dynamics before and after anti-PD-1 therapy in basal or squamous cell carcinoma suggests the newly entered T cell clonotypes, rather than the exhausted T cell clonotypes, respond to anti-PD-1 immunotherapy (79).